| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 13.74% | Piper Sandler | $11 → $12 | Maintains | Neutral |
| 11/08/2023 | 51.66% | Morgan Stanley | $17 → $16 | Maintains | Equal-Weight |
| 10/30/2023 | 13.74% | Stifel | $13 → $12 | Maintains | Hold |
| 08/14/2023 | 23.22% | Piper Sandler | $9 → $13 | Maintains | Neutral |
| 08/09/2023 | -9.95% | Goldman Sachs | $8.5 → $9.5 | Maintains | Sell |
| 08/08/2023 | -9.95% | Goldman Sachs | $8.5 → $9.5 | Maintains | Sell |
| 04/26/2023 | -14.69% | Goldman Sachs | $10.5 → $9 | Maintains | Sell |
| 04/25/2023 | -14.69% | Goldman Sachs | $10.5 → $9 | Maintains | Sell |
| 04/20/2023 | 32.7% | Barclays | → $14 | Upgrades | Equal-Weight → Overweight |
| 02/22/2023 | 32.7% | Barclays | $18 → $14 | Maintains | Equal-Weight |
| 01/30/2023 | 80.09% | Morgan Stanley | $20 → $19 | Maintains | Equal-Weight |
| 11/15/2022 | 89.57% | Morgan Stanley | $21 → $20 | Maintains | Equal-Weight |
| 11/14/2022 | 42.18% | Piper Sandler | $21 → $15 | Maintains | Neutral |
| 11/09/2022 | 13.74% | Goldman Sachs | $19 → $12 | Maintains | Sell |
| 10/17/2022 | 89.57% | JP Morgan | $24 → $20 | Maintains | Neutral |
| 10/07/2022 | 99.05% | Morgan Stanley | $22 → $21 | Maintains | Equal-Weight |
| 09/12/2022 | 70.62% | Barclays | $32 → $18 | Maintains | Equal-Weight |
| 08/18/2022 | 108.53% | Morgan Stanley | $37 → $22 | Downgrades | Overweight → Equal-Weight |
| 08/17/2022 | 99.05% | Piper Sandler | $22 → $21 | Maintains | Neutral |
| 08/16/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 07/21/2022 | 80.09% | Goldman Sachs | $32 → $19 | Downgrades | Buy → Sell |
| 07/18/2022 | 203.32% | JP Morgan | $37 → $32 | Maintains | Overweight |
| 07/12/2022 | 108.53% | Piper Sandler | → $22 | Initiates Coverage On | → Neutral |
| 06/24/2022 | 108.53% | Stifel | $30 → $22 | Maintains | Hold |
| 05/19/2022 | 203.32% | Goldman Sachs | $37 → $32 | Maintains | Buy |
| 05/17/2022 | 250.71% | Morgan Stanley | $40 → $37 | Maintains | Overweight |
| 02/28/2022 | 203.32% | Barclays | $30 → $32 | Maintains | Equal-Weight |
| 11/18/2021 | 279.15% | Morgan Stanley | → $40 | Initiates Coverage On | → Overweight |
| 10/28/2021 | 222.27% | Stifel | $37 → $34 | Downgrades | Buy → Hold |
| 05/11/2021 | — | Gabelli & Co. | Upgrades | Hold → Buy | |
| 05/11/2021 | 174.88% | Barclays | $25 → $29 | Upgrades | Underweight → Equal-Weight |
| 04/15/2021 | 250.71% | Stifel | → $37 | Initiates Coverage On | → Buy |
| 03/22/2021 | 203.32% | Gabelli & Co. | → $32 | Downgrades | Buy → Hold |
| 02/26/2021 | 260.19% | Credit Suisse | $33 → $38 | Upgrades | Neutral → Outperform |
| 11/24/2020 | 288.63% | Morgan Stanley | $31 → $41 | Maintains | Overweight |
| 11/23/2020 | 288.63% | Morgan Stanley | $31 → $41 | Maintains | Overweight |
| 11/17/2020 | 231.75% | Citigroup | $32 → $35 | Maintains | Buy |
| 08/20/2020 | 193.84% | Morgan Stanley | → $31 | Upgrades | Equal-Weight → Overweight |
| 08/13/2020 | 155.92% | Credit Suisse | → $27 | Reinstates | → Neutral |
| 08/04/2020 | 151.18% | Goldman Sachs | → $26.5 | Reinstates | → Buy |
| 07/27/2020 | 80.09% | Cleveland Research | → $19 | Downgrades | Neutral → Underperform |
| 07/20/2020 | 165.4% | B of A Securities | $26 → $28 | Maintains | Buy |
| 05/15/2020 | 155.92% | Citigroup | $35 → $27 | Maintains | Buy |
| 04/02/2020 | — | Morgan Stanley | Downgrades | Overweight → Equal-Weight | |
| 01/10/2020 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 12/19/2019 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 11/20/2019 | 165.4% | UBS | $30 → $28 | Maintains | Neutral |
| 11/07/2019 | 203.32% | Morgan Stanley | $34 → $32 | Upgrades | Equal-Weight → Overweight |
| 09/23/2019 | 241.23% | Barclays | → $36 | Initiates Coverage On | → Overweight |
| 08/26/2019 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 08/15/2019 | 184.36% | UBS | $31 → $30 | Upgrades | Sell → Neutral |
| 05/23/2019 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 05/10/2019 | 231.75% | BMO Capital | $32 → $35 | Maintains | Market Perform |
| 03/20/2019 | 165.4% | UBS | $29 → $28 | Reinstates | → Sell |
| 03/18/2019 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 02/12/2019 | — | William Blair | Initiates Coverage On | → Market Perform | |
| 01/23/2019 | — | UBS | Initiates Coverage On | → Sell | |
| 01/15/2019 | 250.71% | Argus Research | → $37 | Initiates Coverage On | → Buy |
What is the target price for Elanco Animal Health (ELAN)?
The latest price target for Elanco Animal Health (NYSE: ELAN) was reported by Piper Sandler on November 13, 2023. The analyst firm set a price target for $12.00 expecting ELAN to rise to within 12 months (a possible 13.74% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Elanco Animal Health (ELAN)?
The latest analyst rating for Elanco Animal Health (NYSE: ELAN) was provided by Piper Sandler, and Elanco Animal Health maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Elanco Animal Health (ELAN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elanco Animal Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elanco Animal Health was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Elanco Animal Health (ELAN) correct?
While ratings are subjective and will change, the latest Elanco Animal Health (ELAN) rating was a maintained with a price target of $11.00 to $12.00. The current price Elanco Animal Health (ELAN) is trading at is $10.55, which is out of the analyst's predicted range.